These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35844038)

  • 1. Pharmacokinetic Characteristics, Safety, and Tolerability of Telitacicept, an Injectable Recombinant Human B-Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein, in Healthy Chinese Subjects.
    Xie J; Fan X; Su Y; Zhou H; Cao S; Zhu X; Zhu M; He C; Wang Y; Fan L; Ge Q; Zhu J; Liu B; Chen X; Xie Y; Ma L; Liu Y; Chen J; Wang H; Li Z
    Clin Pharmacol Drug Dev; 2022 Nov; 11(11):1273-1283. PubMed ID: 35844038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease.
    Shi F; Xue R; Zhou X; Shen P; Wang S; Yang Y
    Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):666-673. PubMed ID: 34519594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects.
    Willen D; Uhl W; Wolna P; Papasouliotis O; Yalkinoglu Ö
    Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):27-40. PubMed ID: 31529406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus.
    Fan Y; Gao D; Zhang Z
    Drugs Today (Barc); 2022 Jan; 58(1):23-32. PubMed ID: 35107091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telitacicept: A novel horizon in targeting autoimmunity and rheumatic diseases.
    Zeng L; Yang K; Wu Y; Yu G; Yan Y; Hao M; Song T; Li Y; Chen J; Sun L
    J Autoimmun; 2024 Sep; 148():103291. PubMed ID: 39146891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, pharmacodynamics, and tolerability of single ascending doses of RCT-18 in Chinese patients with rheumatoid arthritis.
    Chen X; Hou Y; Jiang J; Zhao Q; Zhong W; Wang W; Yao X; Li L; Fang J; Zhang F; Hu P
    Clin Pharmacokinet; 2014 Nov; 53(11):1033-44. PubMed ID: 25179916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telitacicept: First Approval.
    Dhillon S
    Drugs; 2021 Sep; 81(14):1671-1675. PubMed ID: 34463932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria.
    Lv J; Liu L; Hao C; Li G; Fu P; Xing G; Zheng H; Chen N; Wang C; Luo P; Xie D; Zuo L; Li R; Mao Y; Dong S; Zhang P; Zheng H; Wang Y; Qin W; Wang W; Li L; Jiao W; Fang J; Zhang H
    Kidney Int Rep; 2023 Mar; 8(3):499-506. PubMed ID: 36938094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telitacicept for Recalcitrant Cutaneous Manifestations of Systemic Lupus Erythematosus: A Case Report and Review of the Literature.
    Ma X; Fu X; Cui B; Lin H
    Tohoku J Exp Med; 2022 Oct; 258(3):219-223. PubMed ID: 36047131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of telitacicept, a BLyS/APRIL dual inhibitor, in the treatment of IgA nephropathy: a retrospective case-control study.
    Wang M; Ma J; Yao L; Fan Y
    Clin Kidney J; 2024 Oct; 17(10):sfae285. PubMed ID: 39391591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case Report: Telitacicept in treating a patient with NF155+ autoimmune nodopathy: a successful attempt to manage recurrent elevated sero-anti-NF155 antibodies.
    Ren Y; Chen S; Yang H
    Front Immunol; 2023; 14():1279808. PubMed ID: 37965304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, Pharmacodynamics, Safety, and Clinical Activity of Multiple Doses of RCT-18 in Chinese Patients With Systemic Lupus Erythematosus.
    Zhao Q; Chen X; Hou Y; Jiang J; Zhong W; Yao X; Wang W; Li L; Fang J; Zhang F; Hu P
    J Clin Pharmacol; 2016 Aug; 56(8):948-59. PubMed ID: 26634642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers.
    Munafo A; Priestley A; Nestorov I; Visich J; Rogge M
    Eur J Clin Pharmacol; 2007 Jul; 63(7):647-56. PubMed ID: 17473917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, safety and tolerability of Bencycloquidium bromide, a novel selective muscarinic M1/M3 receptor antagonist, after single and multiple intranasal doses in healthy chinese subjects: an open-label, single-center, first-in-human study.
    Sun L; Ding L; Wang Y; Zhou W; Yan Z; Sun W; Zhang H; Ou N; Chen X
    Drugs R D; 2012 Mar; 12(1):17-28. PubMed ID: 22339483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacokinetics and safety profiles of belimumab after single subcutaneous and intravenous doses in healthy Japanese volunteers.
    Shida Y; Takahashi N; Sakamoto T; Ino H; Endo A; Hirama T
    J Clin Pharm Ther; 2014 Feb; 39(1):97-101. PubMed ID: 24117862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B cell pathway dual inhibition for systemic lupus erythematosus: a prospective single-arm cohort study of telitacicept.
    Ji L; Geng Y; Zhang X; Deng X; Song Z; Tan M; Tan Y; Qu C; Zhang Z
    MedComm (2020); 2024 Apr; 5(4):e515. PubMed ID: 38525109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of BLyS inhibits B-cell responses and antibody production for the prevention of chronic transplant rejection.
    Liao T; Shi X; Han F; Wang Y; Zeng W; Liu R; Yan Z; Xia R; Huang Z; Xu J; Miao Y
    J Heart Lung Transplant; 2024 Apr; 43(4):652-662. PubMed ID: 38070662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
    Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
    Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers.
    Shi S; Liu Y; Li Z; Wu J; Zhou X; Zeng F
    Arzneimittelforschung; 2012 Feb; 62(2):75-82. PubMed ID: 22344551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability, pharmacokinetics, and pharmacodynamics of recombinant human parathyroid hormone (1-34) in healthy Chinese subjects.
    Liu Y; Yang C; Li Z; Zhou J; Lv Y; Zhang Y; Zeng F; Shi S
    Clin Ther; 2014 Jun; 36(6):940-52. PubMed ID: 24793535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.